Diabetes and Heart Disease Highlights From ESC 2023 Diabetes and Heart Disease Highlights From ESC 2023

Lead author Mikhail Kosiborod discusses the STEP-HFpEF trial of semaglutide in patients with heart failure with preserved ejection fraction and other highlights in diabetes and CVD from ESC 2023.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news